Kristen Kluska Analyst Performance

Managing Director, Biotechnology Equity Research Analyst at Cantor Fitzgerald

Kristen Kluska is a stock analyst at Cantor Fitzgerald, covering 19 publicly traded companies across a range of sectors. Over the past year, Kristen Kluska has issued 26 stock ratings, including buy and hold recommendations. While full access to Kristen Kluska's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kristen Kluska's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 32 Last 5 Years
Buy Recommendations: 90.63% 29 Buy Ratings
Companies Covered: 19 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	90.6%	29 ratings
Hold	9.4%	3 ratings
Sell	0.0%	0 ratings

Out of 32 total stock ratings issued by Kristen Kluska at Cantor Fitzgerald, the majority (90.6%) have been Buy recommendations, followed by 9.4% Hold.

Best & Worst Calls

Best Call
000000.0%
PTE
Mar 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
00.0%
MBIO
Jan 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	19 companies

Kristen Kluska, an analyst at Cantor Fitzgerald, currently covers 19 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 18 companies	94.7%
	Computer and Technology 1 company	5.3%

Kristen Kluska of Cantor Fitzgerald specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 11 companies	57.9%
MED - GENERIC DRG 2 companies	10.5%
MED - DRUGS 2 companies	10.5%
COMP - SOFTWARE 1 company	5.3%
MED PRODUCTS 1 company	5.3%
PHARMACEUTICAL PREPARATIONS 1 company	5.3%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	5.3%

Time Frame

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
RARE Ultragenyx Pharmaceutical	9/5/2025	Reiterated Rating	$31.38	$105.00	Overweight
PTCT PTC Therapeutics	9/3/2025	Reiterated Rating	$54.87	$118.00	Overweight
MNPR Monopar Therapeutics	8/27/2025	Reiterated Rating	$32.03	$74.00	Overweight
RARE Ultragenyx Pharmaceutical	8/6/2025	Lower Price Target	$26.83	$105.00	Overweight
SUPN Supernus Pharmaceuticals	8/6/2025	Boost Price Target	$41.99	$46.00	Overweight
RIGL Rigel Pharmaceuticals	8/6/2025	Boost Price Target	$27.64	$32.00	Neutral
PTC PTC	7/29/2025	Set Price Target	$202.95	$120.00	Overweight
PTCT PTC Therapeutics	7/29/2025	Boost Price Target	$48.86	$120.00	Overweight
EPRX Eupraxia Pharmaceuticals	7/24/2025	Initiated Coverage	$5.14	$11.00	Overweight
MNPR Monopar Therapeutics	7/7/2025	Initiated Coverage	$35.87	$74.00	Overweight
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
FULC Fulcrum Therapeutics	5/15/2025	Upgrade	$5.63	$10.00	Overweight
CAPR Capricor Therapeutics	5/14/2025	Reiterated Rating	$7.77	$30.00	Overweight
PTCT PTC Therapeutics	5/7/2025	Lower Price Target	$38.93	$112.00	Overweight
RIGL Rigel Pharmaceuticals	5/7/2025	Boost Price Target	$20.51	$23.00	Neutral
TSHA Taysha Gene Therapies	4/28/2025	Reiterated Rating	$1.86	$7.00	Overweight
SLNO Soleno Therapeutics	3/27/2025	Boost Price Target	$48.97	$123.00	Overweight
XFOR X4 Pharmaceuticals	3/26/2025	Reiterated Rating	$7.98	$90.00	Overweight
CAPR Capricor Therapeutics	3/20/2025	Reiterated Rating	$13.86	$30.00	Overweight
IRON Disc Medicine	3/18/2025	Boost Price Target	$51.27	$132.00	Overweight
ADMA ADMA Biologics	3/4/2025	Reiterated Rating	$13.78	$25.00	Overweight
RARE Ultragenyx Pharmaceutical	2/26/2025	Reiterated Rating	$40.80	$118.00	Overweight
PTCT PTC Therapeutics	2/3/2025	Boost Price Target	$49.16	$113.00	Overweight
CLDX Celldex Therapeutics	1/29/2025	Reiterated Rating	$24.23	$67.00	Overweight
RARE Ultragenyx Pharmaceutical	1/22/2025	Reiterated Rating	$42.28	$118.00	Overweight
PTCT PTC Therapeutics	1/15/2025	Lower Price Target	$41.81	$76.00	Overweight
FOLD Amicus Therapeutics	1/15/2025	Reiterated Rating	$9.21	$21.00	Overweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.